2017 Documentation Drug Pricing 
Putting Patients First Blog
JUNE 26, 2025
The NHC supports the efforts to reduce out-of-pocket costs for Medicare beneficiaries and appreciates CMS’ work to establish a process that seeks to incorporate patient perspectives into drug pricing policy. This will allow other stakeholders (e.g.,
Pharmaceutical Technology
JULY 11, 2025
3 GlobalData’s analysis shows that the number of clinical trial investigators globally fell from approximately 128,303 in 2017-18 to 116,948 in 2023-24 – a decline of almost 10%. 9 Rising direct trial costs and lost revenue due to delayed approval are key factors driving the total cost of bringing a new drug to market to a staggering $2.3bn.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 2, 2025
This could transform the current drug pricing model, shifting from regular doses over time to a single treatment. In addition, the TCI market is projected for significant growth, rising from $13m in 2017 to $30bn in 2030, says GlobalData. How will RFK Jr’s American dream for vaccines play out?
Pharmaceutical Technology
SEPTEMBER 15, 2022
According to GlobalData’s Drugs Database, Rinvoq and Skyrizi combined are projected to reach global analyst consensus forecast sales of more than $21bn by 2028. Bristol Myers Squibb (BMS) documented a 9.1%
Putting Patients First Blog
SEPTEMBER 3, 2024
Overall, while the NHC appreciates CMS’ intent to streamline the data submission process and make it more accessible, we encourage ongoing dialogue and adjustments to ensure that the process remains patient-centered, efficient, and capable of capturing the full spectrum of information necessary to inform meaningful drug price negotiations.
Safe Biologics
FEBRUARY 1, 2024
Over the years, the WHO has attempted to evaluate the BQ: a provisional implementation of the programme was suggested in 2016, and in 2017 a pilot BQ project was discussed. Other supporting agencies await the WHO implementing a global system. In 2018, the project was put on hold for data gathering.
Pharmaceutical Technology
JANUARY 6, 2023
In 2020, the Federal Trade Commission issued a report regarding settlements reached between brand and generic manufacturers in FY 2017 and noted that “for the first time since [FY] 2004, no settlement agreement in [FY] 2017 contains a no-[authorized generic] AG commitment.”. Gilenya is an oral medication for multiple sclerosis.
Expert insights. Personalized for you.
Let's personalize your content